Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structure−Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo
- 1 August 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (16) , 5075-5084
Abstract
Quinolone-3-carboxamides 11 bearing at position 5, 6, 7, or 8 diverse substituents such as halides, alkyl, aryl, alkoxy, and aryloxy groups differing in their steric/electronic properties, were prepared. The new compounds were tested in vitro for CB1 and CB2 receptor affinity in comparison with the reference compounds rimonabant and SR144528. The tested compounds exhibited CB2 affinity in the range from 55.9 to 0.8 nM and CB1 affinity in the range from >10 000 to 5.3 nM, with selectivity indeces [Ki(CB1)/Ki(CB2)] varying from >2666.6 to 1.23. On the basis of the structure−selectivity relationship developed, the presence of a substituent at C6/C8 or C7 well accounts for the high or low CB2 selectivity, respectively. Compound 11c, characterized by high CB2 affinity and selectivity, showed analgesic activity in the formalin test of acute peripheral and inflammatory pain in mice as a result of selective CB2 agonistic activity.Keywords
This publication has 30 references indexed in Scilit:
- Latest advances in cannabinoid receptor antagonists and inverse agonistsExpert Opinion on Therapeutic Patents, 2006
- Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking CessationCurrent Medicinal Chemistry, 2006
- Cannabinoids in medicine: A review of their therapeutic potentialJournal of Ethnopharmacology, 2006
- Peripheral cannabinoid receptor, CB2, regulates bone massProceedings of the National Academy of Sciences, 2006
- The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic ApplicationsJournal of Medicinal Chemistry, 2005
- Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonistsDrug Discovery Today, 2005
- Rimonabant HydrochlorideDrugs of the Future, 2005
- The endocannabinoid system and its therapeutic exploitationNature Reviews Drug Discovery, 2004
- CB cannabinoid receptor agonists: pain relief without psychoactive effects?Current Opinion in Pharmacology, 2003
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994